Real-world application of autologous hematopoietic stem cell transplantation in 507 patients with multiple sclerosis

ConclusionIn patients with RRMS, autologous non-myeloablative HSCT is an effective one-time therapy, while HSCT appears of less benefit for newly diagnosed SPMS.

Source: Journal of Neurology - October 11, 2021 Category: Neurology Source Type: research